GEP20022763B - 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor - Google Patents

2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor

Info

Publication number
GEP20022763B
GEP20022763B GEAP20005644A GEAP2000005644A GEP20022763B GE P20022763 B GEP20022763 B GE P20022763B GE AP20005644 A GEAP20005644 A GE AP20005644A GE AP2000005644 A GEAP2000005644 A GE AP2000005644A GE P20022763 B GEP20022763 B GE P20022763B
Authority
GE
Georgia
Prior art keywords
receptor
treatment
diseases caused
production
same
Prior art date
Application number
GEAP20005644A
Other languages
English (en)
Inventor
Andrew Sleight
Thorsten Hoffmann
Theresa Maria Ballard
Sonia Maria Poli
Guy Andrew Higgins
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of GEP20022763B publication Critical patent/GEP20022763B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
GEAP20005644A 1999-11-29 2000-11-27 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor GEP20022763B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
GEP20022763B true GEP20022763B (en) 2002-08-26

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP20005644A GEP20022763B (en) 1999-11-29 2000-11-27 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor

Country Status (49)

Country Link
EP (1) EP1103545B1 (cg-RX-API-DMAC7.html)
JP (1) JP3480835B2 (cg-RX-API-DMAC7.html)
KR (1) KR100390117B1 (cg-RX-API-DMAC7.html)
CN (1) CN1152016C (cg-RX-API-DMAC7.html)
AR (1) AR033659A1 (cg-RX-API-DMAC7.html)
AT (1) ATE253561T1 (cg-RX-API-DMAC7.html)
AU (1) AU775292B2 (cg-RX-API-DMAC7.html)
BG (1) BG64622B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0005616B8 (cg-RX-API-DMAC7.html)
CA (1) CA2326529C (cg-RX-API-DMAC7.html)
CO (1) CO5251405A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ299286B6 (cg-RX-API-DMAC7.html)
DE (2) DE60006340T2 (cg-RX-API-DMAC7.html)
DK (1) DK1103545T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2000000106A (cg-RX-API-DMAC7.html)
EA (1) EA004404B1 (cg-RX-API-DMAC7.html)
ES (2) ES2208205T3 (cg-RX-API-DMAC7.html)
FR (1) FR2801590A1 (cg-RX-API-DMAC7.html)
GB (1) GB2356863A (cg-RX-API-DMAC7.html)
GC (1) GC0000151A (cg-RX-API-DMAC7.html)
GE (1) GEP20022763B (cg-RX-API-DMAC7.html)
GT (1) GT200000197A (cg-RX-API-DMAC7.html)
HR (1) HRP20000809A2 (cg-RX-API-DMAC7.html)
HU (1) HU224703B1 (cg-RX-API-DMAC7.html)
ID (1) ID28483A (cg-RX-API-DMAC7.html)
IL (1) IL139868A (cg-RX-API-DMAC7.html)
IS (1) IS2212B (cg-RX-API-DMAC7.html)
IT (1) IT1320120B1 (cg-RX-API-DMAC7.html)
JO (1) JO2298B1 (cg-RX-API-DMAC7.html)
MA (1) MA26754A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA00011672A (cg-RX-API-DMAC7.html)
MY (1) MY127426A (cg-RX-API-DMAC7.html)
NO (1) NO317264B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ508386A (cg-RX-API-DMAC7.html)
OA (1) OA11513A (cg-RX-API-DMAC7.html)
PA (1) PA8507201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20010901A1 (cg-RX-API-DMAC7.html)
PL (1) PL195957B1 (cg-RX-API-DMAC7.html)
PT (1) PT1103545E (cg-RX-API-DMAC7.html)
SG (1) SG97171A1 (cg-RX-API-DMAC7.html)
SI (1) SI1103545T1 (cg-RX-API-DMAC7.html)
SK (1) SK285373B6 (cg-RX-API-DMAC7.html)
SV (1) SV2002000227A (cg-RX-API-DMAC7.html)
TN (1) TNSN00226A1 (cg-RX-API-DMAC7.html)
TR (1) TR200302077T4 (cg-RX-API-DMAC7.html)
UA (1) UA70326C2 (cg-RX-API-DMAC7.html)
UY (1) UY26458A1 (cg-RX-API-DMAC7.html)
YU (1) YU73400A (cg-RX-API-DMAC7.html)
ZA (1) ZA200006964B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2238264C2 (ru) 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
EP1303490B1 (en) * 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
PL371731A1 (en) * 2002-01-31 2005-06-27 F.Hoffmann-La Roche Ag Genetic polymorphisms in the preprotachykinin gene
HRP20070471T3 (hr) 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
EP1776342B1 (en) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
CA2602445C (en) 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
NZ566419A (en) 2005-09-23 2010-03-26 Hoffmann La Roche Novel dosage formulation
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
DK3102208T4 (da) 2014-02-07 2024-08-26 Global Blood Therapeutics Inc Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919245A3 (en) * 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE364606T1 (de) * 1993-12-29 2007-07-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
NO309272B1 (no) * 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
EP1303490B1 (en) * 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
CZ20004399A3 (cs) 2001-07-11
IT1320120B1 (it) 2003-11-18
EA004404B1 (ru) 2004-04-29
CN1297888A (zh) 2001-06-06
AU775292B2 (en) 2004-07-29
IL139868A0 (en) 2002-02-10
HUP0004725A2 (hu) 2002-04-29
BRPI0005616B1 (pt) 2017-12-12
JP2001151754A (ja) 2001-06-05
KR20010051983A (ko) 2001-06-25
SG97171A1 (en) 2003-07-18
MXPA00011672A (es) 2002-08-20
HU224703B1 (en) 2006-01-30
DK1103545T3 (da) 2004-03-15
CA2326529A1 (en) 2001-05-29
IS2212B (is) 2007-02-15
HK1036759A1 (en) 2002-01-18
CZ299286B6 (cs) 2008-06-04
IL139868A (en) 2009-09-01
PT1103545E (pt) 2004-03-31
CO5251405A1 (es) 2003-02-28
MY127426A (en) 2006-11-30
NO317264B1 (no) 2004-09-27
HU0004725D0 (cg-RX-API-DMAC7.html) 2001-02-28
AR033659A1 (es) 2004-01-07
SV2002000227A (es) 2002-02-05
BG64622B1 (bg) 2005-09-30
PA8507201A1 (es) 2002-02-21
CA2326529C (en) 2009-12-22
FR2801590A1 (fr) 2001-06-01
SK17932000A3 (sk) 2001-11-06
TNSN00226A1 (fr) 2002-05-30
PL344147A1 (en) 2001-06-04
EA200001114A3 (ru) 2001-12-24
PL195957B1 (pl) 2007-11-30
KR100390117B1 (ko) 2003-07-04
JO2298B1 (en) 2005-09-12
MA26754A1 (fr) 2004-12-20
PE20010901A1 (es) 2001-09-20
DOP2000000106A (es) 2002-07-30
DE60006340D1 (de) 2003-12-11
UY26458A1 (es) 2001-05-31
DE10058310A1 (de) 2001-05-31
CN1152016C (zh) 2004-06-02
EA200001114A2 (ru) 2001-08-27
TR200302077T4 (tr) 2004-01-21
GB2356863A (en) 2001-06-06
HRP20000809A2 (en) 2001-12-31
EP1103545B1 (en) 2003-11-05
BG104992A (en) 2001-11-30
ZA200006964B (en) 2001-06-05
GB0028566D0 (en) 2001-01-10
ITMI20002575A1 (it) 2002-05-29
SI1103545T1 (en) 2004-02-29
BR0005616A (pt) 2001-07-17
BRPI0005616B8 (pt) 2021-07-06
AU7178700A (en) 2001-05-31
ATE253561T1 (de) 2003-11-15
ES2171134A1 (es) 2002-08-16
ID28483A (id) 2001-05-31
OA11513A (fr) 2004-02-03
IS5725A (is) 2001-05-29
JP3480835B2 (ja) 2003-12-22
GT200000197A (es) 2002-05-22
NZ508386A (en) 2003-02-28
NO20006012L (no) 2001-05-30
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
YU73400A (sh) 2003-02-28
NO20006012D0 (no) 2000-11-28
ES2208205T3 (es) 2004-06-16
EP1103545A1 (en) 2001-05-30
SK285373B6 (sk) 2006-12-07
UA70326C2 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
GEP20022763B (en) 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
GEP20022653B (en) Processes and Intermediates for Preparing Anti-Cancer Compounds
ID26128A (id) Senyawa-senyawa aminotetralin tersubstitusi-n sebagai ligan-ligan untuk reseptor neupeptida y y5 yang bermanfaat dalam pengobatan obesitas dan gangguan-gangguan lain
FI952607A0 (fi) Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE9904505D0 (sv) Novel compounds
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
GEP20033116B (en) New Esters Derived From Substituted Phenyl-Cyclohexyl Compounds, Methods for Their Production for Preparation Drug with Analgesic Properties
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
SE9900961D0 (sv) Novel compounds
SE9802208D0 (sv) Novel compounds
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
NZ515304A (en) Bradykinin receptor antagonists
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
GEP20053617B (en) Bridged Piperazine Derivatives
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
SE9802209D0 (sv) Novel compounds